• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Tuesday, January 26, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home Aging

Deep Longevity publishes an epigenetic aging clock of unprecedented accuracy

Bioengineer by Bioengineer
December 8, 2020
in Aging, Bioinformatics, Biology, Cell Biology, Gerontology, Medicine/Health, Molecular Biology
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

DeepMAge is an epigenetic aging clock with a 2.77 years error margin, which makes it the most accurate DNAm clock to date. The clock shows association with cancer, dementia, obesity, and other age-related conditions

IMAGE

Credit: Fedor Galkin

8 December 2020 — Deep Longevity, a Hong-Kong based longevity startup, has published their research on the epigenetics of aging in the Aging and Disease journal.

The article about DeepMAge describes a novel aging clock that was trained to predict human age on more than 6’000 DNA methylation profiles [1]. By analyzing the methylation patterns it can estimate human age within a 3-year error margin, which is more accurate than any other human aging clock [2].

Aging clocks boom started in 2013 when the first DNA methylation aging clocks by Horvath and Hannum were published [3, 4]. They have proven to be an indispensable tool in aging research, letting scientists understand its mechanisms and develop longevity interventions. Unlike its predecessors, DeepMAge is a neural network that may prove to be more efficient in some other ways apart from prediction accuracy. In the original paper, DeepMAge deems people with certain conditions to be older, which may be useful for the development of early diagnostics tools. For example, women with ovarian cancer are on average predicted 1.7 years older than healthy women of the same chronological age, and likewise, multiple sclerosis patients are predicted 2.1 years older. Similar results have been obtained for several other conditions: irritable bowel diseases, dementia, obesity.

Higher age predictions indicate a faster pace of aging in these conditions, which begs the question: is a higher aging rate a precondition to them or is it just an epigenetic footprint of the harm they cause? The authors plan to further investigate the links between epigenetics and longevity using DeepMAge.

According to an author of the published article, Fedor Galkin: ” Aging clocks have come a long way since the first works by Horvath and Hannum in 2013. We are happy to contribute to this research field. Now, we are going to explore how epigenetic aging can be slowed down with the interventions available to consumers”. Neural network architecture, which DeepMAge is based on, can be modified to digitally emulate the effects of fasting, taking longevity supplements, physical training, and other lifestyle changes.

###

Deep Longevity also intends to eventually make DeepMAge available to the public at their web health platform Young.AI.

[1] Fedor Galkin,Polina Mamoshina,Kirill Kochetov, et al. (2020) DeepMAge: A Methylation Aging Clock Developed with Deep Learning. Aging and disease

[2] Galkin F, Mamoshina P, Aliper A, et al (2020) Biohorology and biomarkers of aging: Current state-of-the-art, challenges and opportunities. Ageing Res. Rev.

[2] Hannum G, Guinney J, Zhao L, et al (2013) Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell

[3] Horvath S (2013) DNA methylation age of human tissues and cell types. Genome Biol

About Deep Longevity

Deep Longevity is currently the subject of a conditional acquisition by Regent Pacific Group Limited (SEHK:0575.HK), a public company whose securities are listed in Hong Kong. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed “deep aging clocks” to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other experts AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.
deeplongevity.com

About Regent Pacific (SEHK:0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness, and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.
regentpac.com

“Deep Longevity is currently the subject to a conditional acquisition by Regent Pacific Group Limited (SEHK:0575.HK), a public company whose securities are listed in Hong Kong

Media Contact
Fedor Galkin
[email protected]

Deep Longevity publishes an epigenetic aging clock of unprecedented accuracy

Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

Breakthrough design at UBCO vastly improves mechanical heart valve

January 26, 2021
IMAGE

How fast could SARS-CoV-2 be detected?

January 25, 2021

Anti-freeze for cell membranes

January 25, 2021

Bioorthogonally catalyzed lethality strategy generates targeting drugs within tumor

January 25, 2021
Next Post
IMAGE

New study allows regional prediction of uranium in groundwater

IMAGE

SMART researchers design portable device for fast detection of plant stress

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    The map of nuclear deformation takes the form of a mountain landscape

    54 shares
    Share 22 Tweet 14
  • People living with HIV face premature heart disease and barriers to care

    68 shares
    Share 27 Tweet 17
  • New drug form may help treat osteoporosis, calcium-related disorders

    41 shares
    Share 16 Tweet 10
  • New findings help explain how COVID-19 overpowers the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

BiologyTechnology/Engineering/Computer ScienceInfectious/Emerging DiseasesMedicine/HealthCell BiologyChemistry/Physics/Materials SciencesGeneticscancerClimate ChangeMaterialsPublic HealthEcology/Environment

Recent Posts

  • Highly specific synaptic plasticity in addiction
  • Breakthrough design at UBCO vastly improves mechanical heart valve
  • How did Florida fail to respond to a coral disease epizootic and what’s to follow?
  • Impact of patient-reported symptom information on lumbar spine MRI Interpretation
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In